Chief, Antibody Immunity Section
Stadtman Tenure Track Investigator
Education:
Ph.D., 1998, Cornell University, Ithaca, NY
Biography
Nicole Doria-Rose earned her PhD from Cornell University in 1998, followed by post-doctoral work at the Seattle Biomedical Research Institute. She has been a researcher at the National Institute of Allergy and Infectious Diseases since 2006 and the Vaccine Research Center since 2011. Her goals are to understand the development of broadly neutralizing antibodies (bNAbs) for HIV and COVID, and to use those insights to develop effective vaccines. Her studies of bNAb development in HIV-infected individuals have revealed principles of HIV-antibody co-evolution, suggesting strategies for vaccine design. She developed a high-throughput method for culturing and screening single B cells for antibody discovery, and with this method her team isolated the most potently HIV-neutralizing antibody yet known. Dr. Doria-Rose also led a team to develop a neutralization assay for SARS-CoV-2, the virus that causes COVID-19, and provided data in support of the mRNA vaccines now in use worldwide.